{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:54:52Z","timestamp":1777859692303,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2021,6]]},"abstract":"\n Background:<\/jats:title>\n Sacubitril\/valsartan has been shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, initiation of sacubitril\/valsartan has primarily been studied in stable, ambulatory patients with HFrEF.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n The objective of this study was to determine risk factors for intolerance to inpatient sacubitril\/valsartan initiation.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This was a retrospective, single-center study from August 1, 2015 through April 30, 2018. Patients were at least 18 years old and were newly initiated on sacubitril\/valsartan during their hospitalization.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n A total of 143 patients met inclusion criteria. Of these patients, 20.3% (n = 29) were intolerant to inpatient initiation of sacubitril\/valsartan. The primary reason for intolerance was hypotension (n = 19, 65.5%). Patients with newly diagnosed heart failure were more likely to tolerate the initiation of sacubitril\/valsartan (32.5% vs 10.3%; P = 0.03). No differences between groups were identified among other potential predictors for intolerance to sacubitril\/valsartan, including systolic blood pressure, acutely decompensated heart failure, or serum creatinine. The most common adverse event was hypotension, which occurred in 26.6% (n = 38) of all patients.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The majority of inpatients tolerated sacubitril\/valsartan initiation. Larger, prospective, randomized controlled trials would be helpful in further determining ideal candidates for inpatient sacubitril\/valsartan initiation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/0897190019878948","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:05:41Z","timestamp":1570147541000},"page":"454-458","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk Factors for Intolerance of Inpatient Sacubitril\/Valsartan Initiation"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6841-773X","authenticated-orcid":false,"given":"Caitlin C.","family":"Akerman","sequence":"first","affiliation":[{"name":"WakeMed Health & Hospitals, Raleigh, NC, USA"},{"name":"UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janna C.","family":"Beavers","sequence":"additional","affiliation":[{"name":"WakeMed Health & Hospitals, Raleigh, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"issue":"6","key":"bibr1-0897190019878948","first-page":"e137","volume":"136","author":"Yancy CW","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"bibr2-0897190019878948","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"bibr3-0897190019878948","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181ca3eb4"},{"key":"bibr4-0897190019878948","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2007.10.011"},{"key":"bibr5-0897190019878948","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.1.61"},{"key":"bibr6-0897190019878948","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.040"},{"key":"bibr7-0897190019878948","doi-asserted-by":"crossref","unstructured":"Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril\/valsartan in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilization: primary results of the TRANSITION study. Paper presented at: European Society of Cardiology August 25-29, 2018; Munich, Germany.","DOI":"10.1093\/eurheartj\/ehy564.P886"},{"key":"bibr8-0897190019878948","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190019878948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190019878948","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190019878948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:35:44Z","timestamp":1777509344000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190019878948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/0897190019878948"],"URL":"https:\/\/doi.org\/10.1177\/0897190019878948","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,3]]}}}